Unilateral Radiotherapy for the Treatment of Tonsil Cancer

被引:81
作者
Chronowski, Gregory M. [1 ]
Garden, Adam S. [1 ]
Morrison, William H. [1 ]
Frank, Steven J. [1 ]
Schwartz, David L. [3 ]
Shah, Shalin J. [1 ]
Beadle, Beth M. [1 ]
Gunn, G. Brandon [1 ]
Kupferman, Michael E. [2 ]
Ang, Kian K. [1 ]
Rosenthal, David I. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[3] Long Isl Jewish Med Ctr, Dept Radiat Med, New Hyde Pk, NY USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 83卷 / 01期
关键词
Unilateral; Tonsil; Radiotherapy; Neck; Failure; SQUAMOUS-CELL HEAD; NECK-CANCER; RADIATION-THERAPY; CARCINOMA; ONCOLOGY;
D O I
10.1016/j.ijrobp.2011.06.1975
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess, through a retrospective review, clinical outcomes of patients with squamous cell carcinoma of the tonsil treated at the M. D. Anderson Cancer Center with unilateral radiotherapy techniques that irradiate the involved tonsil region and ipsilateral neck only. Methods and Materials: Of 901 patients with newly diagnosed squamous cell carcinoma of the tonsil treated with radiotherapy at our institution, we identified 102 that were treated using unilateral radiotherapy techniques. All patients had their primary site of disease restricted to the tonsillar fossa or anterior pillar, with <1 cm involvement of the soft palate. Patients had TX (n = 17 patients), T1 (n = 52), or T2 (n = 33) disease, with Nx (n = 3), N0 (n = 33), N1 (n = 23), N2a (n = 21), or N2b (n = 22) neck disease. Results: Sixty-one patients (60%) underwent diagnostic tonsillectomy before radiotherapy. Twenty-seven patients (26%) underwent excision of a cervical lymph node or neck dissection before radiotherapy. Median follow-up for surviving patients was 38 months. Locoregional control at the primary site and ipsilateral neck was 100%. Two patients experienced contralateral nodal recurrence (2%). The 5-year overall survival and disease-free survival rates were 95% and 96%, respectively. The 5-year freedom from contralateral nodal recurrence rate was 96%. Nine patients required feeding tubes during therapy. Of the 2 patients with contralateral recurrence, 1 experienced an isolated neck recurrence and was salvaged with contralateral neck dissection only and remains alive and free of disease. The other patient presented with a contralateral base of tongue tumor and involved cervical lymph node, which may have represented a second primary tumor, and died of disease. Conclusions: Unilateral radiotherapy for patients with TX-T2, N0-N2b primary tonsil carcinoma results in high rates of disease control, with low rates of contralateral nodal failure and a low incidence of acute toxicity requiring gastrostomy. (C) 2012 Elsevier Inc.
引用
收藏
页码:204 / 209
页数:6
相关论文
共 17 条
[1]   Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer [J].
Adelstein, DJ ;
Li, Y ;
Adams, GL ;
Wagner, H ;
Kish, JA ;
Ensley, JF ;
Schuller, DE ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :92-98
[2]   Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer [J].
Ang, K. Kian ;
Harris, Jonathan ;
Wheeler, Richard ;
Weber, Randal ;
Rosenthal, David I. ;
Nguyen-Tan, Phuc Felix ;
Westra, William H. ;
Chung, Christine H. ;
Jordan, Richard C. ;
Lu, Charles ;
Kim, Harold ;
Axelrod, Rita ;
Silverman, C. Craig ;
Redmond, Kevin P. ;
Gillison, Maura L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01) :24-35
[3]   A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients [J].
Bjordal, K ;
de Graeff, A ;
Fayers, PM ;
Hammerlid, E ;
van Pottelsberghe, C ;
Curran, D ;
Ahlner-Elmqvist, M ;
Maher, EJ ;
Meyza, JW ;
Brédart, A ;
Söderholm, AL ;
Arraras, JJ ;
Feine, JS ;
Abendstein, H ;
Morton, RP ;
Pignon, T ;
Huguenin, P ;
Bottomly, A ;
Kaasa, S .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1796-1807
[4]   Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[5]  
Chavaudra J, 2001, Cancer Radiother, V5, P472, DOI 10.1016/S1278-3218(01)00117-2
[6]   Contralateral parotid-sparing radiotherapy in patients with unilateral squamous cell carcinoma of the head and neck:: Technical methodology and preliminary results [J].
Corvò, R ;
Foppiano, F ;
Bacigalupo, A ;
Berretta, L ;
Benasso, M ;
Vitale, V .
TUMORI JOURNAL, 2004, 90 (01) :66-72
[7]   Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma [J].
Denis, F ;
Garaud, P ;
Bardet, E ;
Alfonsi, M ;
Sire, C ;
Germain, T ;
Bergerot, P ;
Rhein, B ;
Tortochaux, J ;
Calais, G .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :69-76
[8]   Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma [J].
Garden, Adam S. ;
Morrison, William H. ;
Wong, Pei-Fong ;
Tung, Sam S. ;
Rosenthal, David I. ;
Dong, Lei ;
Mason, Brian ;
Perkins, George H. ;
Ang, K. Kian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02) :438-444
[9]   Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma? [J].
Garden, AS ;
Asper, JA ;
Morrison, WH ;
Schechter, NR ;
Glisson, BS ;
Kies, MS ;
Myers, JN ;
Ang, KK .
CANCER, 2004, 100 (06) :1171-1178
[10]  
Gillison Maura L, 2009, Eur J Cancer, V45 Suppl 1, P383, DOI 10.1016/S0959-8049(09)70058-9